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Recently, b-arrestin1 has been indicated as a prostate cancer promoter through promoting cell proliferation and epithelial to mesenchymal transition, but its underlying mechanism remains unclear. Here, our data revealed that b-arrestin1 could promote cell growth through inhibiting the transcriptional activity and expression of FOXO3a in prostate cancer cells in vitro and in vivo. We found that b-arrestin1 could promote the cell and tumor growth of prostate cancer, and b-arrestin1 expression rep- Although androgen-ablation therapies initially lead to disease regression, advanced PCa ultimately progresses to castration-resistant prostate cancer (CRPC), which is refractory to androgen-ablation therapies and remains the major challenge for the treatment of PCa.
To overcome the resistance of PCa to androgen-ablation therapies, it is essential to investigate the underlying mechanisms of CRPC cell proliferation and apoptosis.
b-arrestin1 is one of the well-known negative regulators of Gprotein-coupled receptor (GPCR) signaling. Accumulating evidence reveals that b-arrestin1 can also serve as an adaptor to guide signals from distinct pathways that play important roles in cell proliferation, apoptosis and cancer progression through interacting with different signaling molecules. 2, 3 Recently, b-arrestin1 has been identified as a potential tumor promoter by promoting cell proliferation and epithelial to mesenchymal transition in PCa, but its underlying mechanism is still not well clarified 4, 5 The Forkhead box-O (FOXO) class of transcription factors in mammalian consists of 4 members (FOXO1, FOXO3a, FOXO4 and FOXO6) that play a pivotal role in tumor suppression through regulating multiple genes that are involved in cell cycle arrest, DNA damage repair, apoptosis and energy metabolism. [6] [7] [8] In PCa, FOXO1 and FOXO3a are the predominantly expressed members of the FOXO subfamily. 9 Previous studies have revealed that decreased transcriptional expressions and activities of FOXO1 and FOXO3a were correlated with increasing tumor grade and associated with cancer progression. [10] [11] [12] [13] In addition, both FOXO1 and FOXO3a are involved in the regulation of cell apoptosis, proliferation and invasion in PCa. 9, [14] [15] [16] [17] [18] [19] [20] However, the precise molecular mechanism of the abnormal expression of FOXO remains unclear.
In the present study, we investigated the role of FOXO in b- 2 | ME TH ODS
| Cell culture and drugs
All prostate cell lines, including RWPE-1, LNCaP, C4-2, PC3 and DU145, were purchased from ATCC (USA) and cultured, as recommended, in a humidified incubator containing 5% CO 2 at 37°C. and epidermal growth factor (EGF) were purchased from R&D Systems. The proteasome inhibitor MG132, PI3-K inhibitor LY294002
and ERK1/2 inhibitor U0126 were purchased from Selleck Chemicals.
| Cell transfection and plasmids
Short hairpin RNA (shRNA) was synthesized by RiBoBio (China) as previously described. 5 The shRNA sequence targeting human b-arrestin1
The sequence of unrelated shRNA was 5 0 -TTCTCCGAACGTGTCACGT-3 0 (shRNA-NC). The full lengths of b-arrestin1, FOXO3a and MDM2 were cloned into a modified pEGFP-N1 vector or pcDNA3.1 vector in-frame with HA, respectively. FHRE-Luc was a gift from Michael Greenberg (Addgene plasmid #1789). The luciferase reporter 39 IRS-luc was constructed as previously described. 19 For transient transfections, cells were seeded in 60-mm dishes and transfected at 70% confluence. The transfections were conducted with shRNA or plasmids using Lipofectamine LTX according to the manufacturer's instructions (Invitrogen).
| Cell growth assay
The cell growth was detected using trypan blue staining, MTS and colony formation methods. The cell number was counted in triplicates of samples at indicated time points after transfection. 
| Western blot analysis
Western blot analysis was conducted as previous described. 19 In brief, cells were lysed in RIPA buffer and equal amounts of protein were separated on a 10% SDS polyacrylamide gel, transferred to a nitrocellulose membrane and immunoblotted with antibodies. 
| Correlation test
Public data of b-arrestin1, FOXO1 and FOXO3a expressions in PCa patients were obtained from The Cancer Genome Atlas Project (TCGA). After excluding patients with incomplete information or normal types, 498 PCa patients' paired expression data were analyzed in total.
| Luciferase assay
Cells were plated in 24-well plates and the plasmids were transfected using Lipofectamine LTX according to the manufacturer's instructions. After transfections, cell lysates were prepared, and luciferase activity was determined using the Dual-Luciferase Assay (Promega) according to the manufacturer's instructions. The relative luciferase activity was measured as the ratio of firefly luciferase activity to Renilla luciferase activity.
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| Immunoprecipitation
Immunoprecipitation was conducted as we previously described. 5, 19 In brief, cells were mechanistically broken using a 29-gauge needle in ice-cold RIPA buffer with protease inhibitors and incubated with indicated antibody or control IgG antibody (Santa Cruz) at 4°C
for overnight. The lysate antibody mixture was centrifuged at 2500 g/min for 5 minute and washed 3 times with lysis buffer. The precipitated proteins were eluted with SDS sample buffer for western blot analyses. 
| Nude mice xenograft experiment

| Immunohistochemical staining
Immunohistochemistry was performed on paraffin-embedded tissue sections from xenograft tumors. The tissue samples were fixed, paraffin-embedded, sectioned at 4-lm thickness and then stained according to standard immunohistochemistry protocol. Images were obtained with a PathScope 4S scanner (DigiPath, USA) and quantified using Image Pro Plus software.
| Statistical analysis
The data are reported as the means AE SD of at least 3 independent experiments. The mean differences were compared using ANOVA and the Student's t test. A P-value of <.05 was considered to be statistically significant. uitylation is a key mechanism to FOXO for degradation, 23 we then investigated the effect of b-arrestin1 on FOXO ubiquitylation as previously described 24, 25 and found that the ectopic expression of b-arrestin1 markedly increased the ubiquitylation of FOXO3a but had no significant effect on FOXO1 ubiquitylation ( Figure 3B and Figure S1 ). Moreover, previous studies have revealed that b- | 1837 ( Figure 3C ). In addition, b-arrestin1 significantly accelerated the interaction between FOXO3a and MDM2 ( Figure 3D ). Taken together, these data suggested that b-arrestin1 could downregulate FOXO3a expression, at least partially, through promoting the MDM2-mediated ubiquitylation pathway, whereas it has no obvious effect on FOXO1 expression.
| b-arrestin1 inhibits the transcriptional activity of FOXO3a
As were cultured in a growth medium for 24 h, and the expressions of the indicated proteins were detected using western blot. B, PC3 monoclonal cells were cultured in a growth medium for 24 h and treated with or without MG132 (10 lmol/L) for 6 h; then the cell lysates of PC3 monoclonal cells were subjected to immunoprecipitation with FOXO1 and FOXO3a antibody, respectively, and ubiquitination was detected using western blot with anti-ubiquitin antibody. The cell lysates were probed with anti-GAPDH antibody to demonstrate the total protein expression. C, D, Forty-eight hours after transfection with the indicated plasmids, the cell lysates and immunoprecipitated proteins were analyzed using western blotting with the indicated antibodies. The FOXO3a expression (D, top line) was quantified using ImageJ software. * denotes P ≤ .05
cotransfected into CRPC cells ( Figure 5A ); then the cell growth was detected using MTS and colony formation methods. As shown in Figure 5B , compared with the control group, the cell proliferation F I G U R E 4 b-arrestin1-mediated transcriptional activity of FOXO3a. A, B, Forty-eight hours after transfection with the indicated shRNA, C4-2 cells were incubated in serum-free medium for 1 h and followed by IGF-1 (100 ng/mL) or epidermal growth factor (EGF; 100 ng/mL) stimulation for 10 min. The expressions of the indicated proteins were subsequently detected using western blot. C, D, Forty-eight hours after transfection with the indicated plasmids, RWPE-1 cells were incubated in serum-free medium for 1 h followed by LY294002 (50 lmol/L) or U0126 (10 lmol/L) treatment for 1 h prior to IGF-1 or EGF stimulation (100 ng/mL, 10 min). The expressions of the indicated proteins were subsequently detected using western blot. E, F, RWPE-1 cells were transiently cotransfected with FHRE-Luc or 39 IRS-luc plasmid along with the indicated plasmids. Luciferase measurement and data analysis were performed 24 h after transfection. ** denotes P ≤ .01. N.S., not significant group was significantly lower than that in the PC3-N1 group (Figure 6D) . Together, these results suggested that b-arrestin1 could accelerate PCa growth through, at least in part, decreasing FOXO3a in vivo.
| DISCUSSION
In the present study, our data indicated that b-arrestin1 could promote the cell growth of CRPC cell lines, which is associated with its inhibitory effects on the activity and expression of FOXO3a but not FOXO1, thereby representing a novel potential mechanism of CRPC progress mediated by b-arrestin1.
As negative regulators of GPCR-mediated signaling, b-arrestins, including b-arrestin1 and b-arrestin2, can also function as scaffold proteins and interact with various signaling molecules to regulate different signaling pathways. 3 Previous studies have indicated that b-arrestins play an impressive role in tumor progression through regulating signal transductions which are responsible for tumor viability and metastasis. 2, 28 Although the role of b-arrestin1 in cell survival and proliferation has been well established in ovarian, gastric, lung and breast cancers, 28 and more recently, b-arrestin1 was identified to act as a potential tumor promoter in PCa, its underlying mechanism has still not been well clarified. 4, 5 In the present study, our results revealed that similar to its roles in lung, breast and liver cancer, b-arrestin1 promoted the cell growth of CRPC cells in vitro and in vivo. [29] [30] [31] [32] We investigated the basal expres- had similar effects on IGF-1-induced phosphorylation of FOXO1 and FOXO3a, but EGF stimulation had no significant effect on FOXO1 phosphorylation, which was different from its effect on FOXO3a.
In conclusion, our data revealed that b-arrestin1 could promote the cell growth of CRPC cells through, at least in part, inhibiting and expression will provide useful information for the development of effective therapies against PCa.
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